VORWARTS PHARMA
LIVE

Serial Number

98403934

Owner

Vorwarts Pharma SIA

Attorney

Diana Portna

First Use Date

Feb 1, 2024

Filing Date

Feb 13, 2024

Add to watchlist:

No watchlists yet
View on USPTO

VORWARTS PHARMA Trademark

Serial Number: 98403934 • Registration: 8024806

VORWARTS PHARMA is a trademark filed by Vorwarts Pharma SIA on February 13, 2024. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Vorwarts Pharma SIA (7 trademarks)

Krisjana Barona iela 15
Riga LV-1011 , LV

Entity Type: 16

Trademark Details

Filing Date

February 13, 2024

Registration Date

November 11, 2025

First Use Anywhere

February 1, 2024

First Use in Commerce

February 1, 2024

Published for Opposition

November 12, 2024

Goods & Services

Acai powder dietary supplements; Acaricides; Adjuvants for medical purposes; Albumin dietary supplements; Alginate dietary supplements; Amino acids for medical purposes; Anaesthetics; Analgesics; Anthelmintics; Anti-diabetic pharmaceuticals; Antibacterial pharmaceuticals; Antibiotics; Antiparasitic preparations; Antiseptics; Appetite suppressant pills; Bacterial preparations for medical and veterinary use; Bacteriological preparations for medical and veterinary use; Cardiovascular pharmaceuticals; Casein dietary supplements; Cellulose esters for pharmaceutical purposes; Charcoal for pharmaceutical purposes; Chemical preparations for pharmaceutical or medical purposes, namely, for the treatment of erectile dysfunction, for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, for the treatment of diabetes, for the treatment of cardiovascular and cerebrovascular diseases, for the treatment of anaphylactic reactions;; Dietary supplements with a cosmetic effect; Digestives for pharmaceutical purposes; Enzyme dietary supplements; Enzyme preparations for medical purposes; Ferments for pharmaceutical purposes; Food supplements, namely, anti-oxidants; Glycerine for medical purposes; Haemoglobin; Herbal extracts, other than essential oils, for medical purposes; Infant formula; Inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; Injectable pharmaceuticals for treatment of anaphylactic reactions; Lecithin dietary supplements; Medical preparations for slimming purposes; Medicated candies; Medicinal preparations for the treatment of erectile dysfunction, for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, for the treatment of diabetes, for the treatment of cardiovascular and cerebrovascular diseases, for the treatment of anaphylactic reactions; Mineral dietary supplements; Nutraceuticals for the treatment of erectile dysfunction, ocular disorders or diseases, bacteria-based diseases, diabetes, cardiovascular and cerebrovascular diseases, anaphylactic reactions; Nutraceuticals for use as a dietary supplement; Nutritional supplements; Ocular pharmaceuticals; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of bone fractures; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hypercholesteremia; Pharmaceutical preparations for the treatment of hyperlipidemia; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for the treatment of rectile dysfunction, ocular disorders or diseases, bacteria-based diseases, diabetes, cardiovascular and cerebrovascular diseases, anaphylactic reactions; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, anti-infectives; Pharmaceuticals, namely, antihelmintics; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, psychotropics; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Propolis dietary supplements; Propolis for pharmaceutical purposes; Protein dietary supplements; Vaginal washes for medical purposes; Vermifuges; Vitamin preparations; Wheat germ dietary supplements; Yeast dietary supplements; Yeast for pharmaceutical purposes

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 11, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 11, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Oct 21, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Oct 21, 2025 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Oct 18, 2025 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 18, 2025 AITU
USE AMENDMENT FILED
May 15, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
May 15, 2025 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 24, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Nov 12, 2024 NPUB
PUBLISHED FOR OPPOSITION
Nov 12, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 23, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 3, 2024 CNSA
ASSIGNED TO EXAMINER
Oct 2, 2024 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jun 25, 2024 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 25, 2024 NWOS
NEW APPLICATION ENTERED
Feb 13, 2024 NWAP